Simulating Disease to Radically Transform Drug Discovery & Development

Slide 1

The case for AI-driven cancer clinical trials –
The efficacy arm in silico

Read more →

Slide 2

GNS Healthcare Announces a Multi-Year Collaboration with Memorial Sloan Kettering’s Innovation Hub to Advance Precision Medicine in Oncology

Read more →

Slide 3

GNS to Develop the World’s First in silico Patient For Prostate Cancer

Read more →

Slide 3

GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis

Read more →

previous arrow
next arrow

At GNS we leverage our pioneering Causal AI technology to exploit the recent explosive growth of multi-omics and clinical data to create “virtual” (in silico) patients in oncology, neurodegeneration, and immunology and reveal the hidden circuitry of disease.

We can now use Gemini in silico patients to simulate disease progression and drug response at the individual patient level to discover novel drug targets, simulate entire trials to better select patients, and rapidly generate evidence of comparative effectiveness vs other drugs.

Getting to the Why…

Slide

Which candidate drug target is driving the clinical endpoint? And through what mechanism?

Slide

Which patients respond or don’t respond to a drug and why?

Slide

Which drug combo improves the clinical efficacy of my drug and why?

Slide

Will Drug A drive better clinical outcomes than Drug B? And if so, why?

previous arrow
next arrow

Meet Gemini

The in silico Patient™

Gemini – The in silico Patient™ is fueled by rich multiomics and clinical data and links drug treatment to patient characteristics to the complex genetic and molecular mechanisms and pathways driving clinical outcomes, enabling the simulation of disease progression and drug response at an individual patient level.

Gemini Solutions →

Gemini Solutions

Fueling Drug Discovery

Uncover novel drug targets
Discover prognostic markers
Identify best combo therapies

Learn more →

Accelerating Clinical Trials

Conduct head-to-head in silico trials
Reveal responding / non-responding populations & underlying mechanisms

Learn more →

Driving Market Access

Generate comparative effectiveness evidence
Inform line of therapy changes
Enable optimal treatment sequencing

Learn more →

A breakthrough approach backed by decades of research …

Coming soon

Bruce Church headshotWhy Causal Learning is a Superpower for Healthcare

Learn more →

GNS by the numbers

60+

Peer-reviewed publications

7

Of top 10 biopharmaceutical companies as customers

12

Disease-specific data partners

1010

Average number of “virtual experiments” conducted per Gemini model

Our Partners & Customers